Screening for ALK rearrangements in lung cancer: Time for a new generation of diagnostics?

Oncologist

Volumn 21, Issue 6, 2016, Pages 662-663

  Dagogo Jack, Ibiayi ^a   Shaw, Alice T ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; PROTEIN TYROSINE KINASE;

ALK GENE; CANCER SCREENING; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GENE; GENE DELETION; GENE REARRANGEMENT; HUMAN; IMMUNOHISTOCHEMISTRY; NOTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; GENETICS; LUNG TUMOR; NON SMALL CELL LUNG CANCER;

CARCINOMA, NON-SMALL-CELL LUNG; GENE REARRANGEMENT; HUMANS; LUNG NEOPLASMS; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 84975282738     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2016-0179     Document Type: Note

References (15)

1. Soda M, Choi YL, Enomoto M et al. Identification of the transforming EML4-ALK fusion gene in nonsmall-cell lung cancer. Nature 2007;448:561-566.
2. Takeuchi K, Choi YL, Soda M et al. Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts. Clin Cancer Res 2008;14: 6618-6624.
3. Shaw AT, Yeap BY, Mino-Kenudson M et al. Clinical features and outcome of patients with nonsmall-cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009;27:4247-4253.
4. Kwak EL, Bang YJ, Camidge DR et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363:1693-1703.
5. Shaw AT, Kim DW, Nakagawa K et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013;368:2385-2394.
6. Solomon BJ, Mok T, Kim DW et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 2014;371:2167-2177.
7. Ali SM, Hensing T, Schrock AB et al. Comprehensive genomic profiling identifies a subset of crizotinib-responsive ALK-rearranged non-small cell lung cancer not detected by fluorescence in situ hybridization. The Oncologist 2016;6:762-770.
8. Shaw AT, Solomon B, Kenudson MM. Crizotinb and testing for ALK. JNatl Compr Canc Netw 2011;9: 1335-1341.
9. Ilie MI, Bence C, Hofman V et al. Discrepancies between FISH and immunohistochemistry for assessment of the ALK status are associated with ALK ‘borderline’-positive rearrangements or a high copy number: A potential major issue for anti-ALK therapeutic strategies. Ann Oncol 2015;26:238-244.
10. Mino-Kenudson M, Chirieac LR, Law K et al. A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry. Clin Cancer Res 2010;16:1561-1571.
11. Marchetti A, Di Lorito A, Pace MV et al. ALK protein analysis by IHC staining after recent regulatory changes: A comparison of two widely used approaches, revision of the literature, and a new testing algorithm. J Thorac Oncol 2016;11:487-495.
12. Savic S, Bode B, Diebold J et al. Detection of ALK-positive non-small-cell lung cancers on cytological specimens: High accuracy of immunocytochemistry with the 5A4 clone. J ThoracOncol 2013;8:1004-1011.
13. Ying J, Guo L, Qiu T et al. Diagnostic value of a novel fully automated immunochemistry assay for detection of ALK rearrangement in primary lung adenocarcinoma. Ann Oncol 2013;24:2589-2593.
14. Lantuejoul S, Rouquette I, Blons Het al. French multicentric validation of ALK rearrangement diagnostic in 547 lung adenocarcinomas. Eur Respir J 2015;46:207-218.
15. Pekar-Zlotin M, Hirsch FR, Soussan-Gutman L et al. Fluorescence in situ hybridization, immunohistochemistry, and next-generation sequencing for detection of EML4-ALK rearrangement in lung cancer. The Oncologist 2015;20:316-322.